As you all know the American Society of Heamatology Conference (ASH) is about to start. I have uploaded a few interesting abstracts and will continue to do so over the next few days as a rolling update.
One abstract in particular might interest some of you who are in CMR and are considering stopping imatinib... this one and others can be found on the main menu under 'Conferences'.
Fluctuating Values of Molecular Residual Disease (MRD) without Molecular Progression After Imatinib Discontinuation in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Have Maintained Complete Molecular Response: Implications for Re-Treatment Criteria and Role of Prior Interferon Therapy. A Pilot Study of the French CML Group (FILMC)